{"id":34889,"date":"2017-11-28T17:27:55","date_gmt":"2017-11-28T15:27:55","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=34889"},"modified":"2017-11-28T17:27:55","modified_gmt":"2017-11-28T15:27:55","slug":"revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","title":{"rendered":"Revisi\u00f3n del uso de f\u00e1rmacos biol\u00f3gicos: nuevas estrategias para tratar la psoriasis, la artritis psori\u00e1sica y la enfermedad de Crohn"},"content":{"rendered":"<p style=\"text-align: justify;\">El pasado mi\u00e9rcoles 22 de noviembre tuvo lugar en el COFB el curso <strong><em>Revisi\u00f3n del uso de f\u00e1rmacos biol\u00f3gicos<\/em><\/strong> dirigido a farmac\u00e9uticos comunitarios, de hospitales, de centros de atenci\u00f3n primaria y de la administraci\u00f3n sanitaria.<\/p>\n<p style=\"text-align: justify;\">El curso ten\u00eda por <strong>objetivos principales<\/strong>:<\/p>\n<ul style=\"text-align: justify;\">\n<li style=\"text-align: justify;\">Saber cu\u00e1les son los <strong>objetivos terap\u00e9uticos<\/strong> en diversas patolog\u00edas.<\/li>\n<li>Conocer las <strong>estrategias nuevas para tratar la psoriasis<\/strong>, la artritis psori\u00e1sica y la enfermedad de Crohn.<\/li>\n<li>Mejorar la <strong>pr\u00e1ctica cl\u00ednica<\/strong> y hacer un <strong>mejor uso de las nuevas estrategias terap\u00e9uticas.<\/strong><\/li>\n<li style=\"text-align: justify;\"><strong>Aprender<\/strong> de la experiencia personal en el<strong>uso de f\u00e1rmacos biol\u00f3gicos<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><div class=\"box info\"> Los <strong>f\u00e1rmacos biol\u00f3gicos son el presente y el futuro del tratamiento de muchas enfermedades<\/strong> como el <strong>c\u00e1ncer<\/strong>, la<strong>esclerosis m\u00faltiple<\/strong>, la<strong>artritis reumatoide y psori\u00e1sica<\/strong> )<strong> enfermedad de Crohn<\/strong>. <\/div><\/p>\n<p style=\"text-align: justify;\">La <strong>jornada <\/strong>se inici\u00f3 con la conferencia<strong> &quot;Artritis psori\u00e1sica: inmunomoduladores e importancia de alternativas terap\u00e9uticas&quot; <\/strong>a cargo del dr. Agust\u00ed Sellas, reumat\u00f3logo de la Unidad de Reumatolog\u00eda del Hospital Universitari Vall d&#039;Hebron. En esta conferencia <strong>se abord\u00f3 la epidemiolog\u00eda de la Artritis Psori\u00e0sica<\/strong> y su <strong>frecuencia a estudios poblacionales generales<\/strong>, haciendo referencia a los patrones cl\u00ednicos ya la valoraci\u00f3n cl\u00ednica de la actividad.<\/p>\n<figure id=\"attachment_34912\" aria-describedby=\"caption-attachment-34912\" style=\"width: 794px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/cofb.171115-05.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"size-full wp-image-34912\" title=\"El doctor Agust\u00ed Sellas y las doctoras Anna L\u00f3pez y Luc\u00eda M\u00e1rquez, acompa\u00f1ados por la jefa del Departamento de Formaci\u00f3n y Desarrollo Profesional del COFB, Cristina Rodr\u00edguez.\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/cofb.171115-05.jpg\" alt=\"El doctor Agust\u00ed Sellas i les doctores Anna L\u00f3pez i Luc\u00eda M\u00e1rquez, acompanyats de la cap del Departament de Formaci\u00f3 i Desenvolupament Professional del COFB, Cristina Rodr\u00edguez.\" width=\"794\" height=\"529\" \/><\/a><figcaption id=\"caption-attachment-34912\" class=\"wp-caption-text\">El doctor Agust\u00ed Sellas y las doctoras Anna L\u00f3pez y Luc\u00eda M\u00e1rquez, acompa\u00f1ados por la jefa del Departamento de Formaci\u00f3n y Desarrollo Profesional del COFB, Cristina Rodr\u00edguez.<\/figcaption><\/figure>\n<p style=\"text-align: justify;\">Acto seguido fue el turno de la conferencia<strong>\u00a0\u201cPsoriasis: objetivo, persistencia y uso de biosimilares\u201d<\/strong> que fue cargo de la Dra. Anna L\u00f3pez, del Servicio de Dermatolog\u00eda del Hospital de Santa Cruz y San Pablo. La Dra. L\u00f3pez hizo referencia al<strong>evoluci\u00f3n de los tratamientos de la psoriasis<\/strong>, a los objetivos terap\u00e9uticos y tambi\u00e9n a algunas medidas de evaluaci\u00f3n de la psoriasis como: Body Surface Area (BSA), Psoriasis Area y Severity Index (PASI), o Physicians&#039; Global Assessment (PGA), entre otros.<\/p>\n<p style=\"text-align: justify;\">Otro de los temas que se trat\u00f3 durante la conferencia fue el de <strong>f\u00e1rmacos biosimilares. <\/strong>Se trata de <strong>productos biol\u00f3gicos<\/strong> muy similares al producto de referencia. El biol\u00f3gico biosimilar es creado mediante ingenier\u00eda reversa, a partir de la informaci\u00f3n conocida sobre el producto de referencia. Los f\u00e1rmacos biol\u00f3gicos son producidos por l\u00edneas celulares \u00fanicas mediante bioingenier\u00eda.<\/p>\n<p style=\"text-align: justify;\">Como conclusiones, la Dra. L\u00f3pez destac\u00f3 que <strong>los f\u00e1rmacos biosimilares pueden reducir el coste comparado con los f\u00e1rmacos de referencia<\/strong> y que la situaci\u00f3n actual permite la extrapolaci\u00f3n de indicaciones por parte de las agencias reguladoras. Tambi\u00e9n es necesaria una definici\u00f3n m\u00e1s precisa sobre la intercambiabilidad y valorar la implicaci\u00f3n en la interpretaci\u00f3n de cambios en eficiencia y seguridad, importante para el m\u00e9dico prescriptor. El objetivo es conseguir el blanqueamiento del paciente<strong> (eficacia)<\/strong>, mantener al paciente blanqueado el m\u00e1ximo tiempo posible <strong>(supervivencia)<\/strong>, mantener al paciente blanqueado con el menor coste posible <strong>(eficiencia) <\/strong>y mantener al paciente con la mejor calidad de vida posible. La probabilidad de \u00e9xito es inversamente proporcional a la complejidad del paciente.<\/p>\n<figure id=\"attachment_34914\" aria-describedby=\"caption-attachment-34914\" style=\"width: 689px\" class=\"wp-caption aligncenter\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/cofb.171115-22.jpg\"><img decoding=\"async\" class=\"size-full wp-image-34914\" title=\"El dr. Agust\u00ed Sellas, durante la conferencia &quot;Artritis psori\u00e1sica: inmunomoduladores e importancia de alternativas terap\u00e9uticas&quot;.\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/cofb.171115-22.jpg\" alt=\"El Dr. Agust\u00ed Sellas, durant la confer\u00e8ncia &quot;Artritis psori\u00e0sica: immunomoduladors i import\u00e0ncia d'alternatives terap\u00e8utiques&quot;.\" width=\"689\" height=\"459\" \/><\/a><figcaption id=\"caption-attachment-34914\" class=\"wp-caption-text\">El doctor Agust\u00ed Sellas, durante la conferencia &quot;Artritis psori\u00e1sica: inmunomoduladores e importancia de alternativas terap\u00e9uticas&quot;.<\/figcaption><\/figure>\n<p style=\"text-align: justify;\">Por \u00faltimo, la \u00faltima conferencia fue <strong>&quot;Enfermedad de Crohn: definici\u00f3n del tratamiento ideal y nuevas mol\u00e9culas para tratarla&quot;\u00a0<\/strong>y corri\u00f3 a cargo de la Dra. Luc\u00eda M\u00e1rquez, digest\u00f3loga adjunta de la Unidad de Enfermedad Inflamatoria Intestinal, del Servicio Digestivo del Hospital del Mar.<\/p>\n<p style=\"text-align: justify;\">A lo largo de la exposici\u00f3n se explic\u00f3 qu\u00e9 es una <strong>Enfermedad Inflamatoria Intestinal (MII). <\/strong>Se trata de una enfermedad cr\u00f3nica de etolog\u00eda multifactorial, que afecta al trato gastrointestinal con un curso recurrente. Tambi\u00e9n se expuso en qu\u00e9 consiste la <strong>colitis ulcerosa<\/strong> (afectaci\u00f3n continua desde el recto limitada a la mucosa) y la <b>enfermedad de Crohn <\/b>(afectaci\u00f3n de cualquier tramo del tracto digestivo, transmural y frecuentemente enfermedad perianal).<\/p>\n<p style=\"text-align: justify;\">La colitis ulcerosa y la enfermedad de Crohn son <strong>enfermedades complejas y polig\u00e9nicas<\/strong> y dependen de: <strong>factores ambientales<\/strong>, <strong>barrera intestinal<\/strong>, <strong>factores gen\u00e9ticos<\/strong>, <strong>flora intestinal<\/strong> y <strong>inmunidad innata-adquirida<\/strong>.<\/p>\n<p><div class=\"box note\"> El <strong>tratamiento<\/strong> <strong>de la enfermedad de Crohn<\/strong> es <strong>diferente seg\u00fan:<\/strong><\/p>\n<ul>\n<li>la gravedad del brote<\/li>\n<li>la extensi\u00f3n de la afectaci\u00f3n<\/li>\n<li>el patr\u00f3n<\/li>\n<li>las manifestaciones extraintestinales<\/li>\n<li>la fase de actividad<\/li>\n<li>si est\u00e1 inactiva (tratamiento de mantenimiento)<\/li>\n<li>los antecedentes patol\u00f3gicos (neoplasias, infecciones\u2026) <\/div><\/li>\n<\/ul>\n<p>Para concluir, la Dra. L. M\u00e1rquez hizo referencia tambi\u00e9n a las <strong>nuevas estrategias del tratamiento de la enfermedad de Crohn (una enfermedad de incidencia creciente en los pa\u00edses occidentales, ligada a la industrializaci\u00f3n)<\/strong>, la necesidad de establecer con la mayor certeza posible la actividad real de la enfermedad (muchos pacientes asintom\u00e1ticos con actividad y sintom\u00e1ticos sin lesiones) y la necesidad de incorporar a los ensayos cl\u00ednicos medidas de actividad objetivas.<\/p>\n<p style=\"text-align: right;\">\u00a0 <strong>Con la colaboraci\u00f3n de:<\/strong><\/p>\n<p style=\"text-align: right;\"><a href=\"https:\/\/www.janssen.com\/es\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"wp-image-41846 alignright\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/11\/Janssen.jpg\" alt=\"\" width=\"172\" height=\"84\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Otras informaciones relacionadas recogidas en el Blog:<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/blog.cofb.cat\/jornada-formativa-sobre-psoriasi-el-paper-del-farmaceutic-en-la-millora-del-seu-control\/\" target=\"_blank\" rel=\"noopener\">Jornada formativa sobre psoriasis y el papel del faramc\u00e9utico en la mejora de su control (Septiembre 2017)<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/arriba-barcelona-la-campanya-de-conscienciacio-activacio-aclareix-la-psoriasi\/\" target=\"_blank\" rel=\"noopener\">Llega a Barcelona la campa\u00f1a de concienciaci\u00f3n y activaci\u00f3n \u201cAclara la psoriasis\u201d (Junio 2017)<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/els-farmaceutics-actualitzen-coneixements-en-melatonina-dermatitis-atopica\/\" target=\"_blank\" rel=\"noopener\">Los farmac\u00e9uticos actualizan conocimientos en melatonina y dermatidos at\u00f3pica (Junio 2017)<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/lexposicio-psoriasi-el-que-la-pell-amaga-arriba-terrassa-per-sensibilitzar-sobre-la-gravetat-daquesta-malaltia\/\" target=\"_blank\" rel=\"noopener\">La exposici\u00f3n \u201cPsoriasis, lo que la piel esconde\u201d llega a Terrassa para sensibilizar sobre la gravedad de esta enfermedad (Octubre 2016)<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/5-de-maig-jornada-sobre-psoriasi-i-artritis-psoriasica-a-barcelona\/\" target=\"_blank\" rel=\"noopener\">5 de mayo: jornada sobre psoriasis y artritis psor\u00e1sica en Barcelona (Mayo 2016)<\/a><\/li>\n<\/ul>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>El pasado mi\u00e9rcoles 22 de noviembre tuvo lugar en el COFB el curso Revisi\u00f3n del uso de f\u00e1rmacos biol\u00f3gicos dirigido a farmac\u00e9uticos comunitarios, hospitales, centros de atenci\u00f3n primaria y administraci\u00f3n sanitaria. El curso ten\u00eda por objetivos principales: Saber cu\u00e1les son los objetivos terap\u00e9uticos en diversas patolog\u00edas. Conocer las estrategias [\u2026]<\/p>","protected":false},"author":1,"featured_media":34914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[209,2929,18,54,70,222,231],"class_list":["post-34889","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-artritis-psoriasica","tag-biologics","tag-cofb","tag-farmacs","tag-formacio","tag-malaltia-de-crohn","tag-psoriasi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Revisi\u00f3 de l&#039;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#039;artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"Revisi\u00f3 de l&#039;\u00fas de f\u00e0rmacs biol\u00f2gics\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revisi\u00f3 de l&#039;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#039;artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Revisi\u00f3 de l&#039;\u00fas de f\u00e0rmacs biol\u00f2gics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-28T15:27:55+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn\",\"datePublished\":\"2017-11-28T15:27:55+00:00\",\"dateModified\":\"2017-11-28T15:27:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\"},\"wordCount\":979,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"artritis psori\u00e0sica\",\"biol\u00f2gics\",\"COFB\",\"f\u00e0rmacs\",\"Formaci\u00f3\",\"malaltia de crohn\",\"psoriasi\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\",\"name\":\"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l'artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2017-11-28T15:27:55+00:00\",\"dateModified\":\"2017-11-28T15:27:55+00:00\",\"description\":\"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l'artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","og_locale":"es_ES","og_type":"article","og_title":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l'artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics","og_url":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2017-11-28T15:27:55+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn","datePublished":"2017-11-28T15:27:55+00:00","dateModified":"2017-11-28T15:27:55+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/"},"wordCount":979,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage"},"thumbnailUrl":"","keywords":["artritis psori\u00e0sica","biol\u00f2gics","COFB","f\u00e0rmacs","Formaci\u00f3","malaltia de crohn","psoriasi"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","url":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/","name":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l'artritis psori\u00e0sica i la malaltia de Crohn - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage"},"thumbnailUrl":"","datePublished":"2017-11-28T15:27:55+00:00","dateModified":"2017-11-28T15:27:55+00:00","description":"Revisi\u00f3 de l'\u00fas de f\u00e0rmacs biol\u00f2gics","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2017\/11\/28\/revisio-de-lus-de-farmacs-biologics-noves-estrategies-per-tractar-la-psoriasi-lartritis-psoriasica-i-la-malaltia-de-crohn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics: noves estrat\u00e8gies per tractar la psoriasi, l&#8217;artritis psori\u00e0sica i la malaltia de Crohn"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat dimecres 22 de novembre va tenir lloc al COFB el curs Revisi\u00f3 de l&#8217;\u00fas de f\u00e0rmacs biol\u00f2gics adre\u00e7at a farmac\u00e8utics comunitaris, d&#8217;hospitals, de centres d&#8217;atenci\u00f3 prim\u00e0ria i de l&#8217;administraci\u00f3 sanit\u00e0ria. El curs tenia per objectius principals: Saber quins s\u00f3n els objectius terap\u00e8utics en diverses patologies. Con\u00e8ixer les estrat\u00e8gies [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/34889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=34889"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/34889\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=34889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=34889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=34889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}